

Drug Policy

Policy:	Antiseizure Medications - Topiramate Step Therapy	Annual Review Date: 09/19/2024
Impacted Drugs:	Eprontia, topiramate capsule ER 24 hour sprinkle (generic to Qudexy XR), topiramate capsule extended release 24 hour (generic to Trokendi XR), Trokendi XR	Last Revised Date: 09/19/2024

OVERVIEW

Topiramate is a sulphamate-substituted monosaccharide derived from D-fructose. Although the exact mechanism of action is unknown topiramate can produce antiepileptic and antimigraine effects. Immediate-release preparations are bioequivalent (sprinkle capsule and tablet). However, the extended-release formulations Qudexy XR and Trokendi XR are not bioequivalent or interchangeable.

As a monotherapy topiramate can be used to treat certain types of seizures, including partial onset or primary generalized tonic-clonic seizures. And as adjunct treatment for seizures associated with Lennox-Gaustaut syndrome. Most topiramate products can be used in patients 2 years of age or older for seizures, except Trokendi XR patients must be 6 years of age or older.

Topiramate may also be used for preventative treatment of migraine headache in patients must be 12 years of age or older.

POLICY STATEMENT

A preferred step therapy program has been developed to encourage the use of a preferred product prior to the use of a non-preferred product. If the preferred step therapy rule is not met for a non-preferred agent at the point of service, coverage will be determined by the preferred step therapy criteria below. All approvals are provided for 1 year in duration.

*Note: Trokendi XR with DAW9 indicates that substitution is allowed by the prescriber but the Plan requests brand.

Automation: A patient with a history of one preferred medication within the 365-day look-back period is excluded from step therapy.

Preferred Medications

- Generic topiramate tablets
- Generic topiramate sprinkle capsules

Non-Preferred Medications

- Eprontia
- topiramate capsule ER 24 hour sprinkle (generic to Qudexy XR)
- topiramate capsule extended release 24 hour (generic to Trokendi XR)
- Trokendi XR*

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

PREFERRED STEP THERAPY CRITERIA

1. If the patient has tried a preferred medication, then authorization for a non-preferred medication may be given.

Initial Approval/ Extended Approval.

- A) *Initial Approval:* 2 years
B) *Extended Approval:* 2 years
-

Step Therapy Exception Criteria

Approve for 1 year if the patient meets the following (A, B, or C):

- A. The patient has an atypical diagnosis and/or unique patient characteristics which prevent use of all preferred agents. If so, please list diagnosis and/or patient characteristics [documentation required]; **OR**
- B. The patient has a contraindication to all preferred agents. If so, please list the contraindications to each preferred agent [documentation required]; **OR**
- C. The patient is continuing therapy with the requested non-preferred agent after being stable for at least 90 days [verification in prescription claims history required] or, if not available, [verification by prescribing physician required] AND meets ONE of the following:
 1. The patient has at least 130 days of prescription claims history on file and claims history supports that the patient has received the requested non-preferred agent for 90 days within a 130-day look-back period AND there is no generic equivalent available for the requested nonpreferred product (i.e. AA-rated or AB-rated to the requested nonpreferred product); **OR**
 2. When 130 days of the patient's prescription claims history file is unavailable for verification, the prescriber must verify that the patient has been receiving the requested non-preferred agent for 90 days AND that the patient has been receiving the requested non-preferred agent via paid claims (i.e. the patient has NOT been receiving samples or coupons or other types of waivers in order to obtain access to the requested non-preferred agent) AND there is no generic equivalent available for the requested nonpreferred product (i.e. AA-rated or AB-rated to the requested nonpreferred product).

Documentation Required: When documentation is required, the prescriber must provide written documentation supporting the trials of these other agents, noted in the criteria as [documentation required]. Documentation should include chart notes, prescription claims records, and/or prescription receipts.

Approval Duration: All approvals for continuation of therapy are provided for 1 year unless noted otherwise below. In cases where the initial approval is authorized in months, 1 month is equal to 30 days.

Documentation Requirements:

Drug Policy

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

REFERENCES

1. Topamax® tablets, sprinkle capsules [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; June 2020.
2. Trokendi XR® extended-release capsules [prescribing information]. Rockville, MD: Supernus Pharmaceuticals, Inc.; February 2019.
3. Qudexy® XR extended-release capsules [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, Inc.; February 2020.
4. Eprontia® oral solution [prescribing information]. Wilmington, MA: Azurity Pharmaceuticals.; November 2021.